Joseph R. Winer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joseph R. Winer has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
Elizabeth C. Mormino
Department of Neurology & Neurological Sciences Stanford University School of Medicine Palo Alto California USA
8 shared publications- Kathleen L. Poston
Department of Neurology and Neurological Sciences, Stanford University School of Medicine
5 shared publications Theresa M. Harrison
University of California, Berkeley, Berkeley, CA, USA
5 shared publicationsAmerica Romero
Department of Neurology & Neurological Sciences Stanford University School of Medicine Palo Alto California USA
4 shared publicationsChristina B. Young
Department of Neurology & Neurological Sciences Stanford University School of Medicine Palo Alto California USA
4 shared publicationsHillary Vossler
Department of Neurology & Neurological Sciences Stanford University School of Medicine Palo Alto California USA
4 shared publications
Latest Publications
- Open Access
- 22 May 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
A Two‐Stage Questionnaire and Actigraphy Screening for iRBD in a Multicenter Retrospective Cohort
Objective: Isolated rapid‐eye‐movement sleep behavior disorder is a prodromal marker of synucleinopathies. However, most cases remain undiagnosed due to the insufficient predictive value of questionnaires and limited access to confirmatory video‐polysomnography. We assessed a two‐stage screening strategy combining a brief questionnaire on rapid‐eye‐movement sleep behavior disorder symptoms and other prodromes with wrist actigraphy across multiple case–control cohorts. Methods: Participants aged 40–80 without neurodegenerative disease were recruited from five cohorts; all cases were confirmed by video‐polysomnography. The questionnaire was administered to 289 participants, and 236 underwent ≥ 14 nights of home wrist actigraphy. The wearable‐based algorithm was built on four movement features (mean motor activity, activity index, short or long immobile bouts, twitch activity). Models were trained with nested cross‐validation using XGBoost. Results: The full retrospective cohort included 396 participants (99 cases, 297 controls; mean age 64 ± 11; 55% male). The dream enactment question alone achieved an area under the curve of 0.85, which improved to 0.86 using the four‐item questionnaire. Actigraphy alone achieved 82% sensitivity and 84% specificity. In the subgroup completing both assessments (75 cases, 54 controls), the two‐stage protocol—questionnaire followed by actigraphy—yielded 68% sensitivity and 100% specificity using the dream enactment question alone, and 73% sensitivity and 100% specificity using the four‐item questionnaire. Interpretation: A two‐stage protocol combining questionnaire and actigraphy demonstrated high specificity and good sensitivity for detecting isolated rapid‐eye‐movement sleep behavior disorder in this multicenter cohort. This low‐cost, scalable strategy is compatible with widely used wearable devices and warrants validation in community‐based populations.
- 22 May 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
Open AccessA Two‐Stage Questionnaire and Actigraphy Screening for iRBD in a Multicenter Retrospective Cohort
Objective: Isolated rapid‐eye‐movement sleep behavior disorder is a prodromal marker of synucleinopathies. However, most cases remain undiagnosed due to the insufficient predictive value of questionnaires and limited access to confirmatory video‐polysomnography. We assessed a two‐stage screening strategy combining a brief questionnaire on rapid‐eye‐movement sleep behavior disorder symptoms and other prodromes with wrist actigraphy across multiple case–control cohorts. Methods: Participants aged 40–80 without neurodegenerative disease were recruited from five cohorts; all cases were confirmed by video‐polysomnography. The questionnaire was administered to 289 participants, and 236 underwent ≥ 14 nights of home wrist actigraphy. The wearable‐based algorithm was built on four movement features (mean motor activity, activity index, short or long immobile bouts, twitch activity). Models were trained with nested cross‐validation using XGBoost. Results: The full retrospective cohort included 396 participants (99 cases, 297 controls; mean age 64 ± 11; 55% male). The dream enactment question alone achieved an area under the curve of 0.85, which improved to 0.86 using the four‐item questionnaire. Actigraphy alone achieved 82% sensitivity and 84% specificity. In the subgroup completing both assessments (75 cases, 54 controls), the two‐stage protocol—questionnaire followed by actigraphy—yielded 68% sensitivity and 100% specificity using the dream enactment question alone, and 73% sensitivity and 100% specificity using the four‐item questionnaire. Interpretation: A two‐stage protocol combining questionnaire and actigraphy demonstrated high specificity and good sensitivity for detecting isolated rapid‐eye‐movement sleep behavior disorder in this multicenter cohort. This low‐cost, scalable strategy is compatible with widely used wearable devices and warrants validation in community‐based populations.
- Open Access
- 3 May 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (5) , e71455
Effects of α‐synuclein pathology on synaptic dysfunction and clinical outcomes in normal aging
INTRODUCTION: α‐Synuclein is the hallmark pathology of Parkinson's disease and dementia with Lewy bodies, described together as Lewy body disease (LBD). We investigated effects of α‐syn biomarker positivity in clinically unimpaired (CU) individuals. METHODS: We assessed α‐syn status (α‐syn ±) in 269 CU individuals using a cerebrospinal fluid (CSF) seed amplification assay (SAA). Fifty‐six participants with AD and 85 LBD spectrum participants were included for comparison. We compared α‐syn SAA results with demographics, fluid biomarkers, cognitive performance, and clinical measures. RESULTS: α ‐Syn positivity was detected in 9% of CU individuals, a lower rate than in clinically impaired participants with AD (16%) and LBD diagnoses (81%). Compared to α‐syn‐, α‐syn+ CU individuals were older, showed lower synaptic integrity, performed worse on tests of executive function and working memory, and reported more LBD‐related non‐motor symptoms. DISCUSSION: Further work is needed to understand the timeline of neural and clinical changes in α‐syn+ CU individuals and heterogeneity in disease progression.
- 3 May 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (5) , e71455
Open AccessEffects of α‐synuclein pathology on synaptic dysfunction and clinical outcomes in normal aging
INTRODUCTION: α‐Synuclein is the hallmark pathology of Parkinson's disease and dementia with Lewy bodies, described together as Lewy body disease (LBD). We investigated effects of α‐syn biomarker positivity in clinically unimpaired (CU) individuals. METHODS: We assessed α‐syn status (α‐syn ±) in 269 CU individuals using a cerebrospinal fluid (CSF) seed amplification assay (SAA). Fifty‐six participants with AD and 85 LBD spectrum participants were included for comparison. We compared α‐syn SAA results with demographics, fluid biomarkers, cognitive performance, and clinical measures. RESULTS: α ‐Syn positivity was detected in 9% of CU individuals, a lower rate than in clinically impaired participants with AD (16%) and LBD diagnoses (81%). Compared to α‐syn‐, α‐syn+ CU individuals were older, showed lower synaptic integrity, performed worse on tests of executive function and working memory, and reported more LBD‐related non‐motor symptoms. DISCUSSION: Further work is needed to understand the timeline of neural and clinical changes in α‐syn+ CU individuals and heterogeneity in disease progression.
- 26 March 2026
- Published by Oxford University Press (OUP) in Brain
Longitudinal trajectories of divergent cortical tau patterns in preclinical Alzheimer’s disease
Approximately 10% of clinically unimpaired individuals with abnormal amyloid (A+; preclinical Alzheimer’s disease) have ‘divergent’ cortical tau pathology (A+TCortical+), defined as greater than expected tau in cortical regions relative to the medial temporal lobe and/or cortical asymmetry on tau PET in addition to or instead of traditional medial temporal lobe tau burden. Although these A+TCortical+ individuals have subtle cognitive deficits at baseline, the longitudinal imaging and clinical outcomes are unknown. We aimed to characterize longitudinal trajectories of A+TCortical+ individuals compared with other biomarker-defined clinically unimpaired groups, given that identifying those at highest risk for decline is crucial for informing prevention trials and understanding early disease mechanisms. In this longitudinal study, we examined tau PET, MRI, cognitive and functional data from 395 clinically unimpaired participants, aged 65–85 years, enrolled in the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Study. Participants had two to five flortaucipir scans over a mean (standard deviation) follow-up period of 4.7 (1.6) years. Changes in regional and voxelwise tau patterns, atrophy, cognition and functioning were examined. Longitudinal trajectories from A+TCortical+ (n = 34) were compared with preclinical Alzheimer’s disease with elevated tau PET signal in the medial temporal lobe only (A+TMTL+, n = 102), preclinical Alzheimer’s disease without significant tau (A+TMTL−, n = 210) and those without amyloid or tau (A−TMTL−, n = 49). Cortical tau accumulation was fastest in A+TCortical+ (0.018–0.034 standardized uptake value ratios per year), whereas medial temporal lobe tau accumulation was comparable across A+TCortical+, A+TMTL+ and A+TMTL− groups (0.010–0.013 standardized uptake value ratios per year). Tau continued to accumulate in affected regions and contralateral homotopic regions in A+TCortical+ participants with asymmetrical tau at baseline such that asymmetrical patterns were maintained over time. Younger A+TCortical+ participants had an especially fast cortical accumulation rate. The A+TCortical+ group showed significantly greater neurodegeneration and faster clinical decline (Clinical Dementia Rating Scale Sum of Boxes = 0.610 points per year; Mini-Mental State Examination = −0.780 points per year) than all other biomarker-defined subgroups (Clinical Dementia Rating Scale Sum of Boxes = 0.048–0.182 points per year; Mini-Mental State Examination = −0.189–0.006 points per year). In summary, individuals with divergent cortical tau patterns continue to accumulate cortical tau at a faster rate, show greater neurodegeneration and have faster cognitive and functional decline than other preclinical Alzheimer’s disease subgroups. Clinical trials and research examining tau progression and clinical decline in preclinical Alzheimer’s disease without subtyping might be disproportionately influenced by this small, high-risk subgroup.
- 26 March 2026
- Published by Oxford University Press (OUP) in Brain
Longitudinal trajectories of divergent cortical tau patterns in preclinical Alzheimer’s disease
Approximately 10% of clinically unimpaired individuals with abnormal amyloid (A+; preclinical Alzheimer’s disease) have ‘divergent’ cortical tau pathology (A+TCortical+), defined as greater than expected tau in cortical regions relative to the medial temporal lobe and/or cortical asymmetry on tau PET in addition to or instead of traditional medial temporal lobe tau burden. Although these A+TCortical+ individuals have subtle cognitive deficits at baseline, the longitudinal imaging and clinical outcomes are unknown. We aimed to characterize longitudinal trajectories of A+TCortical+ individuals compared with other biomarker-defined clinically unimpaired groups, given that identifying those at highest risk for decline is crucial for informing prevention trials and understanding early disease mechanisms. In this longitudinal study, we examined tau PET, MRI, cognitive and functional data from 395 clinically unimpaired participants, aged 65–85 years, enrolled in the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Study. Participants had two to five flortaucipir scans over a mean (standard deviation) follow-up period of 4.7 (1.6) years. Changes in regional and voxelwise tau patterns, atrophy, cognition and functioning were examined. Longitudinal trajectories from A+TCortical+ (n = 34) were compared with preclinical Alzheimer’s disease with elevated tau PET signal in the medial temporal lobe only (A+TMTL+, n = 102), preclinical Alzheimer’s disease without significant tau (A+TMTL−, n = 210) and those without amyloid or tau (A−TMTL−, n = 49). Cortical tau accumulation was fastest in A+TCortical+ (0.018–0.034 standardized uptake value ratios per year), whereas medial temporal lobe tau accumulation was comparable across A+TCortical+, A+TMTL+ and A+TMTL− groups (0.010–0.013 standardized uptake value ratios per year). Tau continued to accumulate in affected regions and contralateral homotopic regions in A+TCortical+ participants with asymmetrical tau at baseline such that asymmetrical patterns were maintained over time. Younger A+TCortical+ participants had an especially fast cortical accumulation rate. The A+TCortical+ group showed significantly greater neurodegeneration and faster clinical decline (Clinical Dementia Rating Scale Sum of Boxes = 0.610 points per year; Mini-Mental State Examination = −0.780 points per year) than all other biomarker-defined subgroups (Clinical Dementia Rating Scale Sum of Boxes = 0.048–0.182 points per year; Mini-Mental State Examination = −0.189–0.006 points per year). In summary, individuals with divergent cortical tau patterns continue to accumulate cortical tau at a faster rate, show greater neurodegeneration and have faster cognitive and functional decline than other preclinical Alzheimer’s disease subgroups. Clinical trials and research examining tau progression and clinical decline in preclinical Alzheimer’s disease without subtyping might be disproportionately influenced by this small, high-risk subgroup.
- Open Access
A Two-Stage Questionnaire and Actigraphy Screening for Isolated REM Sleep Behavior Disorder in a Multicenter Cohort
Objective: Isolated rapid-eye-movement sleep behavior disorder is a prodromal marker of synucleinopathies. However, most cases remain undiagnosed due to the insufficient predictive value of questionnaires and limited access to confirmatory video-polysomnography. We assessed a two-stage screening strategy combining a brief questionnaire on rapid-eye-movement sleep behavior disorder symptoms and other prodromes with wrist actigraphy across multiple case-control cohorts. Methods: Participants aged 40–80 without neurodegenerative disease were recruited from five cohorts; all cases were confirmed by video-polysomnography. The questionnaire was administered to 289 participants, and 236 underwent ≥14 nights of home wrist actigraphy. The wearable-based algorithm was built on four movement features (mean motor activity, activity index, short or long immobile bouts, twitch activity). Models were trained with nested cross-validation using XGBoost. Results: The full retrospective cohort included 396 participants (99 cases, 297 controls; mean age 64 ± 11; 55% male). The dream enactment question alone achieved an area under the curve of 0.85, which improved to 0.86 using the four-item questionnaire. Actigraphy alone achieved 82% sensitivity and 84% specificity. In the subgroup completing both assessments (75 cases, 54 controls), the two-stage protocol—questionnaire followed by actigraphy—yielded 68% sensitivity and 100% specificity using the dream-enactment question alone, and 73% sensitivity and 100% specificity using the four-item questionnaire. Interpretation: A two-stage protocol combining questionnaire and actigraphy demonstrated high specificity and good sensitivity for detecting isolated rapid-eye-movement sleep behavior disorder in this multicenter cohort. This low-cost, scalable strategy is compatible with widely used wearable devices and warrants validation in community-based populations.
Open AccessA Two-Stage Questionnaire and Actigraphy Screening for Isolated REM Sleep Behavior Disorder in a Multicenter Cohort
Objective: Isolated rapid-eye-movement sleep behavior disorder is a prodromal marker of synucleinopathies. However, most cases remain undiagnosed due to the insufficient predictive value of questionnaires and limited access to confirmatory video-polysomnography. We assessed a two-stage screening strategy combining a brief questionnaire on rapid-eye-movement sleep behavior disorder symptoms and other prodromes with wrist actigraphy across multiple case-control cohorts. Methods: Participants aged 40–80 without neurodegenerative disease were recruited from five cohorts; all cases were confirmed by video-polysomnography. The questionnaire was administered to 289 participants, and 236 underwent ≥14 nights of home wrist actigraphy. The wearable-based algorithm was built on four movement features (mean motor activity, activity index, short or long immobile bouts, twitch activity). Models were trained with nested cross-validation using XGBoost. Results: The full retrospective cohort included 396 participants (99 cases, 297 controls; mean age 64 ± 11; 55% male). The dream enactment question alone achieved an area under the curve of 0.85, which improved to 0.86 using the four-item questionnaire. Actigraphy alone achieved 82% sensitivity and 84% specificity. In the subgroup completing both assessments (75 cases, 54 controls), the two-stage protocol—questionnaire followed by actigraphy—yielded 68% sensitivity and 100% specificity using the dream-enactment question alone, and 73% sensitivity and 100% specificity using the four-item questionnaire. Interpretation: A two-stage protocol combining questionnaire and actigraphy demonstrated high specificity and good sensitivity for detecting isolated rapid-eye-movement sleep behavior disorder in this multicenter cohort. This low-cost, scalable strategy is compatible with widely used wearable devices and warrants validation in community-based populations.
- Open Access
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S2) , e100137
Heterogeneity in associations between short sleep duration and amyloid PET: Comparing US POINTER and A4
Background: Short sleep duration is associated with elevated amyloid PET and other biomarkers of Alzheimer's disease in cognitively unimpaired older adults. Social and structural factors contribute to disparities in sleep across the lifespan, but the impact of sleep health disparities on Alzheimer's disease pathophysiology is not understood. We investigated associations between sleep duration, amyloid PET, and demographic factors in two cohorts of cognitively unimpaired older adults: US POINTER, which emphasized recruitment of individuals with sedentary lifestyles and those from under‐represented groups (URG), and A4, which did not recruit with these emphases. Method: Self‐reported sleep duration, amyloid PET imaging, and demographics were compared for US POINTER participants enrolled in both the neuroimaging and sleep (POINTERzzz) ancillary studies ( N = 426) and A4 participants ( N = 4485). Participants reporting sleep duration <7 hours were categorized as “short sleepers.” Amyloid positivity and centiloids were calculated using 18F‐florbetaben in US POINTER and 18F‐florbetapir in A4 with cohort‐specific processing pipelines. Result: Participants from US POINTER were younger, had fewer years of education, higher CDR sum‐of‐boxes scores, higher BMI, and were more likely to self‐identify as URG compared to A4 participants (Table). US POINTER participants had lower centiloids but the rate of amyloid positivity did not differ between studies. US POINTER participants were much more likely to be short sleepers (76%, versus 27% in A4). Shorter sleep duration was linearly associated with higher centiloids in both cohorts (Figure 1). Logistic regressions revealed that only URG status was significantly associated with short sleep (versus normal sleep) in US POINTER, whereas in A4 short sleep was associated with URG status, lower education, and marginally with higher centiloids. (Figure 2). Shorter sleep duration was significant in predicting amyloid positivity in both cohorts, as was older age. Identifying as Non‐Hispanic White was a significant predictor of amyloid positivity in A4 but was marginal in US POINTER. Conclusion: Self‐reported short sleep duration was associated with amyloid PET in two cognitively unimpaired cohorts, but with different demographic factors associated with short sleep across cohorts. Future work should determine the role of social and structural factors in sleep health, and the potential downstream effect on Alzheimer's pathophysiology.
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S2) , e100137
Open AccessHeterogeneity in associations between short sleep duration and amyloid PET: Comparing US POINTER and A4
Background: Short sleep duration is associated with elevated amyloid PET and other biomarkers of Alzheimer's disease in cognitively unimpaired older adults. Social and structural factors contribute to disparities in sleep across the lifespan, but the impact of sleep health disparities on Alzheimer's disease pathophysiology is not understood. We investigated associations between sleep duration, amyloid PET, and demographic factors in two cohorts of cognitively unimpaired older adults: US POINTER, which emphasized recruitment of individuals with sedentary lifestyles and those from under‐represented groups (URG), and A4, which did not recruit with these emphases. Method: Self‐reported sleep duration, amyloid PET imaging, and demographics were compared for US POINTER participants enrolled in both the neuroimaging and sleep (POINTERzzz) ancillary studies ( N = 426) and A4 participants ( N = 4485). Participants reporting sleep duration <7 hours were categorized as “short sleepers.” Amyloid positivity and centiloids were calculated using 18F‐florbetaben in US POINTER and 18F‐florbetapir in A4 with cohort‐specific processing pipelines. Result: Participants from US POINTER were younger, had fewer years of education, higher CDR sum‐of‐boxes scores, higher BMI, and were more likely to self‐identify as URG compared to A4 participants (Table). US POINTER participants had lower centiloids but the rate of amyloid positivity did not differ between studies. US POINTER participants were much more likely to be short sleepers (76%, versus 27% in A4). Shorter sleep duration was linearly associated with higher centiloids in both cohorts (Figure 1). Logistic regressions revealed that only URG status was significantly associated with short sleep (versus normal sleep) in US POINTER, whereas in A4 short sleep was associated with URG status, lower education, and marginally with higher centiloids. (Figure 2). Shorter sleep duration was significant in predicting amyloid positivity in both cohorts, as was older age. Identifying as Non‐Hispanic White was a significant predictor of amyloid positivity in A4 but was marginal in US POINTER. Conclusion: Self‐reported short sleep duration was associated with amyloid PET in two cognitively unimpaired cohorts, but with different demographic factors associated with short sleep across cohorts. Future work should determine the role of social and structural factors in sleep health, and the potential downstream effect on Alzheimer's pathophysiology.
- Open Access
Cognitive screening biases in a secondary prevention Alzheimer’s disease clinical trial
INTRODUCTION: Alzheimer’s disease (AD) prevention trials have multiple screening steps to identify cognitively unimpaired individuals with AD biomarker evidence. Cognitive/functional screening tests may be biased in underrepresented groups, thereby impacting trial eligibility. METHODS: 6669 participants screened for the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study were grouped by ethnoracial background and testing language. Ethnoracial/language differences in ineligibility reason, cognitive/functional test performance, and amyloid positivity rates were examined. RESULTS: Ethnoracial minorities were least likely to meet eligibility criteria. Patterns of incorrect Mini-Mental State Examination items and impaired Clinical Dementia Rating functional domains differed between groups excluded for impaired cognition/function, suggesting test biases. The Free and Cued Selective Reminding Test yielded more similar exclusion rates across groups than Logical Memory. Cognitive/functional screening biases may impact subsequent biomarker screening as amyloid positivity rates were lowest in ethnoracial minorities. DISCUSSION: Biases in cognitive/functional screening tests may disproportionately exclude ethnoracial minorities in AD prevention trials.
Open AccessCognitive screening biases in a secondary prevention Alzheimer’s disease clinical trial
INTRODUCTION: Alzheimer’s disease (AD) prevention trials have multiple screening steps to identify cognitively unimpaired individuals with AD biomarker evidence. Cognitive/functional screening tests may be biased in underrepresented groups, thereby impacting trial eligibility. METHODS: 6669 participants screened for the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study were grouped by ethnoracial background and testing language. Ethnoracial/language differences in ineligibility reason, cognitive/functional test performance, and amyloid positivity rates were examined. RESULTS: Ethnoracial minorities were least likely to meet eligibility criteria. Patterns of incorrect Mini-Mental State Examination items and impaired Clinical Dementia Rating functional domains differed between groups excluded for impaired cognition/function, suggesting test biases. The Free and Cued Selective Reminding Test yielded more similar exclusion rates across groups than Logical Memory. Cognitive/functional screening biases may impact subsequent biomarker screening as amyloid positivity rates were lowest in ethnoracial minorities. DISCUSSION: Biases in cognitive/functional screening tests may disproportionately exclude ethnoracial minorities in AD prevention trials.
- Open Access
Characterizing amyloid and tau PET-based stages across the clinical continuum
Staging the severity of Alzheimer’s disease pathology using biomarkers is central to early detection and therapeutic trial design. In this cross-sectional study, we standardized amyloid and tau PET data across multiple cohorts to characterize the frequency of amyloid and tau PET-based stages across the clinical continuum. We examined amyloid and tau severity in 10,396 participants (mean [SD] age, 71.9 [7.1] years) with amyloid PET imaging and a subset (n = 3,295) with tau PET imaging. Clinical stage was defined using cohort-specific criteria and categorized as cognitively unimpaired (n = 7,764), mild cognitive impairment (n = 1,480), or dementia (n = 1,152). Amyloid positivity was defined as ≥25 centiloids and amyloid severity was staged using centiloids bins (e.g., <10, 10-24, 25-49, 50-74, 75-99, ≥100). Tau PET severity was staged using a hierarchical Braak staging schema (e.g., T−, T12+, T34+, T56+), and combined with amyloid status to operationalize PET-based Alzheimer’s disease biological stages (e.g., Stage A: A+T−; Stage B: A+T12+; Stage C: A+T34+; Stage D: A+T56+). The cumulative probabilities of PET-based stages were estimated using ordinal logistic regression models. In cognitively unimpaired individuals, the frequency of amyloid levels ≥10 centiloids increased with age. Similarly, amyloid levels ≥25 centiloids increased with age in mild cognitive impairment. Overall, elevated amyloid (≥25 CL) was more likely with increasing age among non-demented individuals. By contrast, this age association was attenuated in dementia where severe amyloid burden (e.g., ≥100 CL) was most common. In the tau PET subsample (n = 3,295), there was a three-way interaction between amyloid, age, and clinical impairment on likelihood of tau severity. Both higher amyloid and greater clinical impairment were associated with increased tau severity; however, the strength and direction of these associations varied with age. At lower amyloid levels, the odds of tau severity increased with older age among cognitively unimpaired and mild cognitive impairment. Conversely, at higher amyloid levels, the odds of higher tau severity (e.g., T56+) decreased with older age in mild cognitive impairment and dementia. A similar age-related pattern was observed in the frequency of biological stages (n = 1,154), where Stage D (e.g., A+T56+) was most frequent in younger individuals with dementia. These findings underscore the dual importance of amyloid and tau PET severity as biomarkers for staging and characterizing Alzheimer’s disease progression. They also demonstrate the feasibility of applying PET-based staging frameworks for the diagnosis of Alzheimer’s disease across multiple tracers and cohorts.
Open AccessCharacterizing amyloid and tau PET-based stages across the clinical continuum
Staging the severity of Alzheimer’s disease pathology using biomarkers is central to early detection and therapeutic trial design. In this cross-sectional study, we standardized amyloid and tau PET data across multiple cohorts to characterize the frequency of amyloid and tau PET-based stages across the clinical continuum. We examined amyloid and tau severity in 10,396 participants (mean [SD] age, 71.9 [7.1] years) with amyloid PET imaging and a subset (n = 3,295) with tau PET imaging. Clinical stage was defined using cohort-specific criteria and categorized as cognitively unimpaired (n = 7,764), mild cognitive impairment (n = 1,480), or dementia (n = 1,152). Amyloid positivity was defined as ≥25 centiloids and amyloid severity was staged using centiloids bins (e.g., <10, 10-24, 25-49, 50-74, 75-99, ≥100). Tau PET severity was staged using a hierarchical Braak staging schema (e.g., T−, T12+, T34+, T56+), and combined with amyloid status to operationalize PET-based Alzheimer’s disease biological stages (e.g., Stage A: A+T−; Stage B: A+T12+; Stage C: A+T34+; Stage D: A+T56+). The cumulative probabilities of PET-based stages were estimated using ordinal logistic regression models. In cognitively unimpaired individuals, the frequency of amyloid levels ≥10 centiloids increased with age. Similarly, amyloid levels ≥25 centiloids increased with age in mild cognitive impairment. Overall, elevated amyloid (≥25 CL) was more likely with increasing age among non-demented individuals. By contrast, this age association was attenuated in dementia where severe amyloid burden (e.g., ≥100 CL) was most common. In the tau PET subsample (n = 3,295), there was a three-way interaction between amyloid, age, and clinical impairment on likelihood of tau severity. Both higher amyloid and greater clinical impairment were associated with increased tau severity; however, the strength and direction of these associations varied with age. At lower amyloid levels, the odds of tau severity increased with older age among cognitively unimpaired and mild cognitive impairment. Conversely, at higher amyloid levels, the odds of higher tau severity (e.g., T56+) decreased with older age in mild cognitive impairment and dementia. A similar age-related pattern was observed in the frequency of biological stages (n = 1,154), where Stage D (e.g., A+T56+) was most frequent in younger individuals with dementia. These findings underscore the dual importance of amyloid and tau PET severity as biomarkers for staging and characterizing Alzheimer’s disease progression. They also demonstrate the feasibility of applying PET-based staging frameworks for the diagnosis of Alzheimer’s disease across multiple tracers and cohorts.
- Open Access
Effects of α-synuclein pathology in normal aging and Alzheimer’s disease
Objective α-synuclein is the hallmark pathology of Parkinson’s disease and dementia with Lewy bodies, described together as Lewy body disease (LBD). α-synuclein is also commonly observed in the context of Alzheimer’s disease (AD). Here we investigate the frequency of α-synuclein biomarker positivity in clinically unimpaired (CU) individuals and an AD research cohort, as well as associations with demographics, AD biomarkers, cognitive performance, and clinical outcomes. Methods We assessed α-synuclein status (α-syn+/-) in 270 CU and 56 clinically diagnosed AD participants (29 mild cognitive impairment and 27 dementia) using a cerebrospinal fluid seed amplification assay (α-syn SAA). Eighty-five LBD spectrum participants were included for comparison. AD biomarker levels were measured with cerebrospinal fluid β-amyloid42/40 and p-tau181. Participants received cognitive testing, the Neuropsychiatric Inventory Questionnaire and the Movement Disorders Society Unified Parkinson’s Disease Rating Scale. Results α-syn was detected in 9% of CU, 14% of AD mild cognitive impairment, and 19% of AD dementia participants, whereas 81% of individuals with LBD spectrum clinical diagnoses were α-syn+. α-syn+ CU were older, performed worse on tests of executive function and working memory, and reported more LBD-related non-motor symptoms relative to α-syn-CU. α-syn status in CU was not significantly associated with β-amyloid or tau, memory performance, motor symptoms, or neuropsychiatric symptoms. Conclusions Using the CSF SAA biomarker, α-syn positivity independently predicts subtle cognitive changes and early clinical symptoms in aging. These cross-sectional findings represent an important addition to the limited but growing literature characterizing the frequency and effects of α-syn positivity in clinically healthy older adults and individuals with AD.
Open AccessEffects of α-synuclein pathology in normal aging and Alzheimer’s disease
Objective α-synuclein is the hallmark pathology of Parkinson’s disease and dementia with Lewy bodies, described together as Lewy body disease (LBD). α-synuclein is also commonly observed in the context of Alzheimer’s disease (AD). Here we investigate the frequency of α-synuclein biomarker positivity in clinically unimpaired (CU) individuals and an AD research cohort, as well as associations with demographics, AD biomarkers, cognitive performance, and clinical outcomes. Methods We assessed α-synuclein status (α-syn+/-) in 270 CU and 56 clinically diagnosed AD participants (29 mild cognitive impairment and 27 dementia) using a cerebrospinal fluid seed amplification assay (α-syn SAA). Eighty-five LBD spectrum participants were included for comparison. AD biomarker levels were measured with cerebrospinal fluid β-amyloid42/40 and p-tau181. Participants received cognitive testing, the Neuropsychiatric Inventory Questionnaire and the Movement Disorders Society Unified Parkinson’s Disease Rating Scale. Results α-syn was detected in 9% of CU, 14% of AD mild cognitive impairment, and 19% of AD dementia participants, whereas 81% of individuals with LBD spectrum clinical diagnoses were α-syn+. α-syn+ CU were older, performed worse on tests of executive function and working memory, and reported more LBD-related non-motor symptoms relative to α-syn-CU. α-syn status in CU was not significantly associated with β-amyloid or tau, memory performance, motor symptoms, or neuropsychiatric symptoms. Conclusions Using the CSF SAA biomarker, α-syn positivity independently predicts subtle cognitive changes and early clinical symptoms in aging. These cross-sectional findings represent an important addition to the limited but growing literature characterizing the frequency and effects of α-syn positivity in clinically healthy older adults and individuals with AD.
- Open Access
- 19 December 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (1) , fcae458
18F-PI-2620 Tau PET is associated with cognitive and motor impairment in Lewy body disease
Co-pathology is frequent in Lewy body disease, which includes clinical diagnoses of both Parkinson’s disease and dementia with Lewy bodies. Measuring concomitant pathology in vivo can improve clinical and research diagnoses and prediction of cognitive trajectories. Tau PET imaging may serve a dual role in Lewy body disease by measuring cortical tau aggregation as well as assessing dopaminergic loss attributed to binding to neuromelanin within substantia nigra. We sought to characterize 18F-PI-2620, a next generation PET tracer, in individuals with Lewy body disease. We recruited 141 participants for 18F-PI-2620 PET scans from the Stanford Alzheimer’s Disease Research Center and the Stanford Aging and Memory Study, most of whom also had β-amyloid status available (139/141) from PET or cerebrospinal fluid. We compared 18F-PI-2620 uptake within entorhinal cortex, inferior temporal cortex, precuneus and lingual gyrus, as well as substantia nigra, across participants with Lewy body disease [Parkinson’s disease (n = 29), dementia with Lewy bodies (n = 14)] and Alzheimer’s disease (n = 28), in addition to cognitively unimpaired healthy older adults (n = 70). Mean bilateral signal was extracted from cortical regions of interest in 18F-PI-2620 standard uptake value ratio (inferior cerebellar grey reference) images normalized to template space. A subset of participants received cognitive testing and/or the Movement Disorders Society Unified Parkinson’s Disease Rating Scale Part III motor exam (off medication). 18F-PI-2620 uptake was low overall in Lewy body disease and correlated with β-amyloid PET in temporal lobe regions and precuneus. Moreover, inferior temporal 18F-PI-2620 uptake was significantly elevated in β-amyloid positive relative to β-amyloid negative participants with Lewy body disease. Temporal lobe 18F-PI-2620 signal was not associated with memory in Lewy body disease, but uptake within precuneus and lingual gyrus was associated with worse executive function and attention/working memory performance. Finally, substantia nigra 18F-PI-2620 signal was significantly reduced in participants with Parkinson’s disease, and lower substantia nigra signal was associated with greater motor impairment. These findings suggest that although levels are lower than in Alzheimer’s disease, small elevations in cortical tau are associated with cognitive function in Lewy body disease relevant domains, and that reduced 18F-PI-2620 binding in substantia nigra may represent loss of dopaminergic neurons. Cortical tau and neuromelanin binding within substantia nigra represent two unique signals in the same PET image that may be informative in the context of cognitive and motor deficits, respectively, in Lewy body disease.
- 19 December 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (1) , fcae458
Open Access18F-PI-2620 Tau PET is associated with cognitive and motor impairment in Lewy body disease
Co-pathology is frequent in Lewy body disease, which includes clinical diagnoses of both Parkinson’s disease and dementia with Lewy bodies. Measuring concomitant pathology in vivo can improve clinical and research diagnoses and prediction of cognitive trajectories. Tau PET imaging may serve a dual role in Lewy body disease by measuring cortical tau aggregation as well as assessing dopaminergic loss attributed to binding to neuromelanin within substantia nigra. We sought to characterize 18F-PI-2620, a next generation PET tracer, in individuals with Lewy body disease. We recruited 141 participants for 18F-PI-2620 PET scans from the Stanford Alzheimer’s Disease Research Center and the Stanford Aging and Memory Study, most of whom also had β-amyloid status available (139/141) from PET or cerebrospinal fluid. We compared 18F-PI-2620 uptake within entorhinal cortex, inferior temporal cortex, precuneus and lingual gyrus, as well as substantia nigra, across participants with Lewy body disease [Parkinson’s disease (n = 29), dementia with Lewy bodies (n = 14)] and Alzheimer’s disease (n = 28), in addition to cognitively unimpaired healthy older adults (n = 70). Mean bilateral signal was extracted from cortical regions of interest in 18F-PI-2620 standard uptake value ratio (inferior cerebellar grey reference) images normalized to template space. A subset of participants received cognitive testing and/or the Movement Disorders Society Unified Parkinson’s Disease Rating Scale Part III motor exam (off medication). 18F-PI-2620 uptake was low overall in Lewy body disease and correlated with β-amyloid PET in temporal lobe regions and precuneus. Moreover, inferior temporal 18F-PI-2620 uptake was significantly elevated in β-amyloid positive relative to β-amyloid negative participants with Lewy body disease. Temporal lobe 18F-PI-2620 signal was not associated with memory in Lewy body disease, but uptake within precuneus and lingual gyrus was associated with worse executive function and attention/working memory performance. Finally, substantia nigra 18F-PI-2620 signal was significantly reduced in participants with Parkinson’s disease, and lower substantia nigra signal was associated with greater motor impairment. These findings suggest that although levels are lower than in Alzheimer’s disease, small elevations in cortical tau are associated with cognitive function in Lewy body disease relevant domains, and that reduced 18F-PI-2620 binding in substantia nigra may represent loss of dopaminergic neurons. Cortical tau and neuromelanin binding within substantia nigra represent two unique signals in the same PET image that may be informative in the context of cognitive and motor deficits, respectively, in Lewy body disease.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S8)
Effects of α‐synuclein pathology in Alzheimer’s disease and normal aging
Background: α‐Synuclein is the hallmark pathology of Parkinson’s disease and dementia with Lewy bodies, described together as Lewy body disease (LBD). α‐Synuclein is also commonly observed in the context of Alzheimer’s disease (AD). Here we investigate the frequency of α‐synuclein positivity in an AD research cohort and clinically unimpaired individuals (CU), as well as associations with demographics and AD biomarkers.Method: We assessed α‐synuclein status (αSyn±) in 69 clinically diagnosed AD (38 mild cognitive impairment and 31 dementia) and 277 CU using a cerebrospinal fluid α‐synuclein seeding aggregation assay. 91 LBD spectrum participants were included for comparison. Aβ status and tau levels were measured with cerebrospinal fluid Aβ42/40 and pTau181 using the Lumipulse G assay. Memory performance was examined in CU individuals enrolled in the Stanford Aging and Memory Study (SAMS, N = 164/277).Result: As expected, αSyn+ was highest in LBD (81%). 16% of AD and 9% of CU were αSyn+. Among αSyn+ CU, 45% were Aβ+ compared to 31% in αSyn‐ CU. In a logistic regression that included only participants with AD, α‐synuclein positivity was associated with male sex, clinical impairment (dementia versus mild cognitive impairment), and higher pTau181 (Figure 1A). In CU, α‐synuclein positivity was associated with older age (Figure 1B). Among CU from SAMS, the αSyn+ group showed cross‐sectional memory reductions that were similar to the A+/T+ CU group (Figure 2).Conclusion: α‐Synuclein status may be an important independent predictor of clinical impairment among individuals on the AD spectrum, as well as subtle memory changes in in aging.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S8)
Open AccessEffects of α‐synuclein pathology in Alzheimer’s disease and normal aging
Background: α‐Synuclein is the hallmark pathology of Parkinson’s disease and dementia with Lewy bodies, described together as Lewy body disease (LBD). α‐Synuclein is also commonly observed in the context of Alzheimer’s disease (AD). Here we investigate the frequency of α‐synuclein positivity in an AD research cohort and clinically unimpaired individuals (CU), as well as associations with demographics and AD biomarkers.Method: We assessed α‐synuclein status (αSyn±) in 69 clinically diagnosed AD (38 mild cognitive impairment and 31 dementia) and 277 CU using a cerebrospinal fluid α‐synuclein seeding aggregation assay. 91 LBD spectrum participants were included for comparison. Aβ status and tau levels were measured with cerebrospinal fluid Aβ42/40 and pTau181 using the Lumipulse G assay. Memory performance was examined in CU individuals enrolled in the Stanford Aging and Memory Study (SAMS, N = 164/277).Result: As expected, αSyn+ was highest in LBD (81%). 16% of AD and 9% of CU were αSyn+. Among αSyn+ CU, 45% were Aβ+ compared to 31% in αSyn‐ CU. In a logistic regression that included only participants with AD, α‐synuclein positivity was associated with male sex, clinical impairment (dementia versus mild cognitive impairment), and higher pTau181 (Figure 1A). In CU, α‐synuclein positivity was associated with older age (Figure 1B). Among CU from SAMS, the αSyn+ group showed cross‐sectional memory reductions that were similar to the A+/T+ CU group (Figure 2).Conclusion: α‐Synuclein status may be an important independent predictor of clinical impairment among individuals on the AD spectrum, as well as subtle memory changes in in aging.